AIDS/IAS: International AIDS Society Conferences

Keri Althoff, Ph.D., discusses how a model developed at Johns Hopkins can assess the comorbidities that patients with HIV may face by 2030.

Improving equity for people with HIV requires health leaders to recognize that patients have different risk factors, Keri Althoff, Ph.D., of Johns Hopkins says.

Phase 3 trials reported at the International AIDS Society meeting this week show no infections among those randomly assigned to twice-year injections of lenacapavir and no reason to be worried about safety,.

The HIV vaccine field has recently faced setbacks with trials like PrepVacc, Mosaico and Imbokodo ending early due to lack of preventive efficacy. Although there have been challenges, scientists have made discoveries showing that the immune system can be prepared to fight HIV with special antibodies.

An overview of the complex relationships between herpes simplex virus, human papillomavirus, cytomegalovirus and HIV.

A substudy of the FLAIR phase 3 trial found that participants favored intramuscular injection of Cabenuva over the subcutaneous version due to pain and the development of nodules and reddening of the skin.

Results from the BEYOND trial show positive clinical outcomes and patient experiences.

Healthcare journalist, HIV advocate and educator Juan Michael Porter II discussed moderating the "Future of Science" session at the International AIDS Society's AIDS 2024 meeting in Munich, Germany, as well as addressing "founder's syndrome" in AIDS organizations and the inclusivity of the event.

Researchers surveyed 201 men who have sex with men and transgender men from 17 clinics who began long-acting cabotegravir to prevent infection with HIV.

At the 25th annual international AIDS Conference in Munich, Germany, a group of international experts discussed the impact of HIV-related stigma and discrimination on efforts to end the HIV pandemic as a public health threat by 2030.

When it comes to preventing and treating patients with HIV/AIDS, experts say to look towards the youth.

There is still much to be done to build on the progress already made in HIV and AIDS, panelists said during a session at the International AIDS Conference.

Results from the DYAD trial reinforce a previous study that found Dovato is not inferior for patients with undetectable viral load who switched from Biktarvy

Inequalities throughout the world in treatment and prevention of HIV are not being addressed, with infection rates rising in the Middle East and north Africa, Eastern Europe and central Asia and Latin America.

The stem cell transplant donor had only one copy of the gene that prevents HIV from entering cells, which opens up the possibility of a cure through gene therapy.